<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425008</url>
  </required_header>
  <id_info>
    <org_study_id>C28001</org_study_id>
    <secondary_id>2012-003397-16</secondary_id>
    <secondary_id>U1111-1164-7508</secondary_id>
    <secondary_id>13/SC/0007</secondary_id>
    <nct_id>NCT01425008</nct_id>
  </id_info>
  <brief_title>Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma</brief_title>
  <official_title>An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study&#xD;
      will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase&#xD;
      will include participants with solid tumors (including melanoma) who have failed or are not&#xD;
      candidates for standard therapies or for whom no approved therapy is available. The Dose&#xD;
      Expansion phase will include participants with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2011</start_date>
  <completion_date type="Actual">October 16, 2018</completion_date>
  <primary_completion_date type="Actual">April 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths</measure>
    <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)</measure>
    <time_frame>Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
    <description>Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Physical Examination Findings</measure>
    <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)</measure>
    <time_frame>Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) Performance Score</measure>
    <time_frame>at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
    <description>ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(&gt;) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair &gt;50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis</measure>
    <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
    <description>ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (&lt;) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline up to the date of first document PD, or death due to any cause, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)</time_frame>
    <description>PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first documented response (CR or PR) up to the date of first documented PD (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)</time_frame>
    <description>DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to &lt;10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580</measure>
    <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 hours [h]) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580</measure>
    <time_frame>Escalation and Expansion Q2D Cohorts: C1D21 pre-dose (C=22 days [Escalation Q2D] and 28 days [Expansion Q2D]); Escalation QW Cohorts: C1D22 pre-dose (C= 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580</measure>
    <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580</measure>
    <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580</measure>
    <time_frame>Q2D Cohorts: Cycle1 Days 1 and 21 up to 24 hours post-dose (Cycle1 length= 22 days); QW Cohorts: Cycle2 Days 1 and 22 up to 7 hours post-dose (Cycle 2 length= 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580</measure>
    <time_frame>Cycle 1 Days 1 and 21 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length= 22 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580</measure>
    <time_frame>Cycle 1 Days 1 and 22 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points</measure>
    <time_frame>Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
    <description>The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points</measure>
    <time_frame>Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
    <description>The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Solid Tumor</condition>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>MLN2480</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN2480</intervention_name>
    <description>Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.</description>
    <arm_group_label>MLN2480</arm_group_label>
    <other_name>TAK-580</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent.&#xD;
&#xD;
          2. Male or female participants 18 years or older.&#xD;
&#xD;
          3. Dose Escalation phase: Participants with solid tumors (including melanoma) who have&#xD;
             failed or are not candidates for standard therapies of for whom no approved therapy is&#xD;
             available.&#xD;
&#xD;
          4. Dose Expansion phase: Metastatic melanoma (locally advanced or metastatic melanoma).&#xD;
&#xD;
          5. Dose Expansion phase: At least 1 measurable lesion which has not been treated&#xD;
             previously with radiotherapy. A newly arising lesion in a previously irradiated field&#xD;
             is acceptable.&#xD;
&#xD;
          6. For participants undergoing biopsy procedures: Prothrombin time (PT) and activated&#xD;
             partial thromboplastin time (aPTT) must be within the normal range.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to&#xD;
             (&lt;=) 1.&#xD;
&#xD;
          8. Adequate tissue sample from either archival formalin-fixed paraffin-embedded (FFPE)&#xD;
             tumor tissue or new biopsy of tumor.&#xD;
&#xD;
          9. Previous chemotherapy, immunotherapy, and hormone therapy must be completed at least 4&#xD;
             weeks prior to the administration of MLN2480 and radiation must be completed at least&#xD;
             3 weeks prior to the administration of MLN2480; all associated toxicity must be&#xD;
             resolved to &lt;=Grade 1.&#xD;
&#xD;
         10. Expected survival time of at least 3 months in the opinion of the investigator.&#xD;
&#xD;
         11. Participants who do not have hypo- or hyperthyroidism.&#xD;
&#xD;
         12. Ability to swallow and retain oral medication.&#xD;
&#xD;
         13. Female participants who are postmenopausal for at least 1 year, surgically sterile, or&#xD;
             agree to practice 2 effective methods of contraception through 3 months after the last&#xD;
             dose of study drug or agree to practice true abstinence.&#xD;
&#xD;
         14. Male participants who, even if surgically sterilized, agree to practice effective&#xD;
             barrier contraception through 3 months after the last dose of alisertib or agree to&#xD;
             practice true abstinence.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History of any major disease that might interfere with safe protocol participation.&#xD;
&#xD;
          2. Dose Expansion phase: Previous treatment with RAF or MEK inhibitors.&#xD;
&#xD;
          3. Laboratory values as specified in study protocol.&#xD;
&#xD;
          4. Current enrollment in any other investigational treatment study.&#xD;
&#xD;
          5. Evidence of current uncontrolled cardiovascular conditions within the past 6 months.&#xD;
&#xD;
          6. Prior investigational agents for malignant or non-malignant disease within 4 weeks&#xD;
             prior to Day 1.&#xD;
&#xD;
          7. Active hepatitis or human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          8. Active bacterial or viral infection.&#xD;
&#xD;
          9. Female participants who are pregnant or currently breastfeeding.&#xD;
&#xD;
         10. Major surgery within 28 days of Day 1.&#xD;
&#xD;
         11. Refractory nausea and vomiting, malabsorption, or significant bowel or stomach&#xD;
             resection.&#xD;
&#xD;
         12. Inability to comply with study requirements.&#xD;
&#xD;
         13. Other unspecified reasons that, in the opinion of the investigator or Millennium, make&#xD;
             the participant unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelmsford</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <results_first_submitted>October 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.&quot;</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT01425008/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT01425008/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 16 investigative sites in the United States and United Kingdom from 13 September 2011 to 16 October 2018.</recruitment_details>
      <pre_assignment_details>Participants with relapsed and refractory solid tumors and metastatic melanoma were enrolled in Dose Escalation Phase and Dose Expansion Phase respectively to receive TAK-580 (MLN2480), once every other day (Q2D) or once weekly (QW). Q2D Dose Expansion Phase, TAK-580 (BRAF+) was discontinued due to sponsor's decision of strategic deprioritization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
          <description>TAK-580 20 milligram (mg), tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P2">
          <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
          <description>TAK-580 40 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P3">
          <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
          <description>TAK-580 80 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P4">
          <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
          <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P5">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P6">
          <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
          <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P7">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P8">
          <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
          <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P9">
          <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P10">
          <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
          <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="P11">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with rapidly accelerated fibrosarcoma (RAF) and mitogen-activated protein kinase (MEPK kinase) or extracellular signal-regulated kinase (ERK kinase) (MEK) inhibitors.</description>
        </group>
        <group group_id="P12">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="P13">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="P14">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="P15">
          <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (wild type [WT]), naive to any prior anticancer therapy except ipilimumab, anti-programmed cell death-1 (PD-1), and anti-PD ligand-1 (PDL-1) monoclonal antibodies.</description>
        </group>
        <group group_id="P16">
          <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
        </group>
        <group group_id="P17">
          <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
          <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
        </group>
        <group group_id="P18">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
        </group>
        <group group_id="P19">
          <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Escalation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic Deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose Expansion Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="16"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="11"/>
                <participants group_id="P17" count="20"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="16"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="11"/>
                <participants group_id="P17" count="20"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="9"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic Deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
      <group_list>
        <group group_id="B1">
          <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
          <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B2">
          <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
          <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B3">
          <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
          <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B4">
          <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
          <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B5">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B6">
          <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
          <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B7">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B8">
          <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
          <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B9">
          <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B10">
          <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
          <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="B11">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="B12">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="B13">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="B14">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="B15">
          <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
        </group>
        <group group_id="B16">
          <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
        </group>
        <group group_id="B17">
          <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
          <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
        </group>
        <group group_id="B18">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
        </group>
        <group group_id="B19">
          <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="B20">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="13"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="16"/>
            <count group_id="B12" value="8"/>
            <count group_id="B13" value="16"/>
            <count group_id="B14" value="1"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="11"/>
            <count group_id="B17" value="20"/>
            <count group_id="B18" value="2"/>
            <count group_id="B19" value="19"/>
            <count group_id="B20" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="10.10"/>
                    <measurement group_id="B2" value="66.3" spread="8.33"/>
                    <measurement group_id="B3" value="56.7" spread="10.26"/>
                    <measurement group_id="B4" value="54.7" spread="13.65"/>
                    <measurement group_id="B5" value="58.7" spread="14.77"/>
                    <measurement group_id="B6" value="65.0" spread="4.40"/>
                    <measurement group_id="B7" value="71.0" spread="6.24"/>
                    <measurement group_id="B8" value="54.7" spread="13.58"/>
                    <measurement group_id="B9" value="57.2" spread="9.34"/>
                    <measurement group_id="B10" value="66.8" spread="7.50"/>
                    <measurement group_id="B11" value="54.6" spread="12.44"/>
                    <measurement group_id="B12" value="58.9" spread="16.39"/>
                    <measurement group_id="B13" value="68.4" spread="7.86"/>
                    <measurement group_id="B14" value="56.0" spread="NA">Standard deviation could not be calculated because only one participant was analysed.</measurement>
                    <measurement group_id="B15" value="56.7" spread="17.24"/>
                    <measurement group_id="B16" value="67.5" spread="8.69"/>
                    <measurement group_id="B17" value="65.1" spread="14.67"/>
                    <measurement group_id="B18" value="50.5" spread="0.71"/>
                    <measurement group_id="B19" value="66.1" spread="11.13"/>
                    <measurement group_id="B20" value="62.5" spread="12.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="9"/>
                    <measurement group_id="B20" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="10"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="12"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="10"/>
                    <measurement group_id="B20" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="16"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="17"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="18"/>
                    <measurement group_id="B20" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="16"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="19"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="19"/>
                    <measurement group_id="B20" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="20"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="11"/>
                    <measurement group_id="B20" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="10"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="7"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="8"/>
                    <measurement group_id="B20" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths</title>
        <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths</title>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="8"/>
                    <measurement group_id="O13" value="16"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="6"/>
                    <measurement group_id="O16" value="11"/>
                    <measurement group_id="O17" value="20"/>
                    <measurement group_id="O18" value="19"/>
                    <measurement group_id="O19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="9"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="11"/>
                    <measurement group_id="O18" value="8"/>
                    <measurement group_id="O19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)</title>
        <description>Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.</description>
        <time_frame>Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)</title>
          <description>Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.</description>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Physical Examination Findings</title>
        <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Physical Examination Findings</title>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="2"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breath sounds abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)</title>
        <time_frame>Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580). Participants who were evaluable for this measure at given time point were included for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)</title>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580). Participants who were evaluable for this measure at given time point were included for the assessment.</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="16"/>
                    <count group_id="O14" value="1"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="11"/>
                    <count group_id="O17" value="20"/>
                    <count group_id="O18" value="19"/>
                    <count group_id="O19" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.477" spread="15.7794"/>
                    <measurement group_id="O2" value="72.077" spread="8.2162"/>
                    <measurement group_id="O3" value="67.375" spread="17.3371"/>
                    <measurement group_id="O4" value="77.717" spread="4.1695"/>
                    <measurement group_id="O5" value="76.963" spread="21.9026"/>
                    <measurement group_id="O6" value="77.695" spread="14.3247"/>
                    <measurement group_id="O7" value="69.522" spread="17.6937"/>
                    <measurement group_id="O8" value="73.589" spread="13.2534"/>
                    <measurement group_id="O9" value="81.054" spread="23.6907"/>
                    <measurement group_id="O10" value="80.503" spread="15.7401"/>
                    <measurement group_id="O11" value="95.837" spread="30.2887"/>
                    <measurement group_id="O12" value="71.288" spread="8.6570"/>
                    <measurement group_id="O13" value="81.312" spread="17.4736"/>
                    <measurement group_id="O14" value="57.100" spread="NA">Standard deviation could not be calculated because only one participant was evaluable</measurement>
                    <measurement group_id="O15" value="75.267" spread="15.3231"/>
                    <measurement group_id="O16" value="72.847" spread="23.8439"/>
                    <measurement group_id="O17" value="79.624" spread="16.6098"/>
                    <measurement group_id="O18" value="83.298" spread="16.3695"/>
                    <measurement group_id="O19" value="67.000" spread="NA">Standard deviation could not be calculated because only one participant was evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOSV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="10"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="13"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="0"/>
                    <count group_id="O15" value="6"/>
                    <count group_id="O16" value="7"/>
                    <count group_id="O17" value="14"/>
                    <count group_id="O18" value="16"/>
                    <count group_id="O19" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.167" spread="16.0315"/>
                    <measurement group_id="O2" value="-1.693" spread="1.4468"/>
                    <measurement group_id="O3" value="1.542" spread="1.1139"/>
                    <measurement group_id="O4" value="-0.907" spread="1.3698"/>
                    <measurement group_id="O5" value="0.065" spread="1.4543"/>
                    <measurement group_id="O6" value="-0.544" spread="3.1033"/>
                    <measurement group_id="O7" value="0.272" spread="1.6037"/>
                    <measurement group_id="O8" value="-1.225" spread="4.5746"/>
                    <measurement group_id="O9" value="-1.868" spread="4.8255"/>
                    <measurement group_id="O10" value="-1.270" spread="0.0005"/>
                    <measurement group_id="O11" value="-7.825" spread="20.1782"/>
                    <measurement group_id="O12" value="-1.700" spread="6.2386"/>
                    <measurement group_id="O13" value="-3.164" spread="3.7607"/>
                    <measurement group_id="O15" value="-3.225" spread="2.9826"/>
                    <measurement group_id="O16" value="0.201" spread="3.7358"/>
                    <measurement group_id="O17" value="-4.292" spread="6.5671"/>
                    <measurement group_id="O18" value="-3.189" spread="3.9690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
        <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings</title>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eastern Cooperative Oncology Group (ECOG) Performance Score</title>
        <description>ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(&gt;) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair &gt;50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.</description>
        <time_frame>at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580). Participants who were evaluable for this measure at given time point were included for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Score</title>
          <description>ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(&gt;) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair &gt;50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.</description>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580). Participants who were evaluable for this measure at given time point were included for the assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="14"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="14"/>
                <count group_id="O18" value="15"/>
                <count group_id="O19" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.00"/>
                    <measurement group_id="O2" value="1.0" spread="1.00"/>
                    <measurement group_id="O3" value="1.7" spread="1.53"/>
                    <measurement group_id="O4" value="0.3" spread="0.58"/>
                    <measurement group_id="O5" value="1.3" spread="0.49"/>
                    <measurement group_id="O6" value="1.2" spread="0.45"/>
                    <measurement group_id="O7" value="1.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.7" spread="0.58"/>
                    <measurement group_id="O9" value="1.0" spread="0.47"/>
                    <measurement group_id="O10" value="1.0" spread="0.00"/>
                    <measurement group_id="O11" value="0.7" spread="0.73"/>
                    <measurement group_id="O12" value="1.5" spread="0.58"/>
                    <measurement group_id="O13" value="0.6" spread="0.90"/>
                    <measurement group_id="O15" value="0.8" spread="0.41"/>
                    <measurement group_id="O16" value="1.2" spread="0.98"/>
                    <measurement group_id="O17" value="0.6" spread="0.74"/>
                    <measurement group_id="O18" value="0.7" spread="0.80"/>
                    <measurement group_id="O19" value="2.0" spread="NA">Standard deviation could not be calculated because only one participant was evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis</title>
        <time_frame>Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis</title>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver function analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="5"/>
                    <measurement group_id="O18" value="2"/>
                    <measurement group_id="O19" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skeletal and cardiac muscle analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="5"/>
                    <measurement group_id="O17" value="6"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mineral and electrolyte analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="2"/>
                    <measurement group_id="O18" value="1"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tissue enzyme analyses NEC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal function analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="4"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pituitary analyses anterior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbohydrate tolerance analyses (incl diabetes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac function diagnostic procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coagulation and bleeding analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digestive enzymes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (&lt;) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.</description>
        <time_frame>Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)</time_frame>
        <population>Response-evaluable population included all participants with measurable disease who received any amount of TAK-580 and had at least 1 postbaseline response assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (&lt;) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.</description>
          <population>Response-evaluable population included all participants with measurable disease who received any amount of TAK-580 and had at least 1 postbaseline response assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="14"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="9"/>
                <count group_id="O17" value="14"/>
                <count group_id="O18" value="17"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="33"/>
                    <measurement group_id="O11" value="50"/>
                    <measurement group_id="O12" value="17"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                    <measurement group_id="O19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.</description>
        <time_frame>Baseline up to the date of first document PD, or death due to any cause, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)</time_frame>
        <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.</description>
          <population>The safety population included all participants who received at least 1 dose of study drug (TAK-580).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="1"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="20"/>
                <count group_id="O18" value="19"/>
                <count group_id="O19" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.8" upper_limit="NA">Upper limit of confidence interval could not be calculated because 75% of the participants had an event.</measurement>
                    <measurement group_id="O2" value="1.4" lower_limit="1.0" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.0" upper_limit="1.5"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.3" upper_limit="2.8"/>
                    <measurement group_id="O6" value="1.2" lower_limit="0.9" upper_limit="32.5"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Median, lower and upper limit of confidence interval could not be calculated because no participant had an event</measurement>
                    <measurement group_id="O8" value="9.2" lower_limit="0.8" upper_limit="9.2"/>
                    <measurement group_id="O9" value="1.5" lower_limit="0.7" upper_limit="1.9"/>
                    <measurement group_id="O10" value="1.9" lower_limit="1.0" upper_limit="NA">Upper limit of confidence interval could not be calculated because 75% of the participants had an event.</measurement>
                    <measurement group_id="O11" value="5.7" lower_limit="1.9" upper_limit="14.3"/>
                    <measurement group_id="O12" value="2.4" lower_limit="1.0" upper_limit="3.7"/>
                    <measurement group_id="O13" value="1.8" lower_limit="1.8" upper_limit="3.2"/>
                    <measurement group_id="O14" value="0.8" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated due to low number of events.</measurement>
                    <measurement group_id="O15" value="1.9" lower_limit="1.8" upper_limit="2.2"/>
                    <measurement group_id="O16" value="1.8" lower_limit="1.7" upper_limit="5.5"/>
                    <measurement group_id="O17" value="3.6" lower_limit="1.8" upper_limit="NA">Upper limit of confidence interval could not be calculated because 50% of the participants were censored.</measurement>
                    <measurement group_id="O18" value="2.3" lower_limit="1.9" upper_limit="5.5"/>
                    <measurement group_id="O19" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to &lt;10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.</description>
        <time_frame>From the first documented response (CR or PR) up to the date of first documented PD (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)</time_frame>
        <population>Analysis population included only a subset of participants (all responders) with response.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O12">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O13">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O14">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O15">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
          </group>
          <group group_id="O16">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O17">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
          <group group_id="O18">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O19">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to &lt;10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.</description>
          <population>Analysis population included only a subset of participants (all responders) with response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="1"/>
                <count group_id="O13" value="1"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="0"/>
                <count group_id="O19" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median, lower and upper limit of confidence interval could not be calculated because no participant had an event</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">Median, lower and upper limit of confidence interval could not be calculated because no participant had an event</measurement>
                    <measurement group_id="O11" value="6.0" lower_limit="3.7" upper_limit="NA">Upper limit of confidence interval could not be calculated because 63% of the participants had an event</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="NA" upper_limit="NA">Median, lower and upper limit of confidence interval could not be calculated because no participant had an event</measurement>
                    <measurement group_id="O13" value="1.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated due to low number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580</title>
        <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 hours [h]) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
        <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580</title>
          <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="86.61"/>
                    <measurement group_id="O2" value="393.1" spread="49.81"/>
                    <measurement group_id="O3" value="921.7" spread="332.40"/>
                    <measurement group_id="O4" value="1048.1" spread="290.91"/>
                    <measurement group_id="O5" value="1933.6" spread="717.03"/>
                    <measurement group_id="O6" value="2675.2" spread="1296.95"/>
                    <measurement group_id="O7" value="2072.8" spread="287.29"/>
                    <measurement group_id="O8" value="2934.0" spread="690.39"/>
                    <measurement group_id="O9" value="4459.3" spread="1475.08"/>
                    <measurement group_id="O10" value="6774.3" spread="1082.79"/>
                    <measurement group_id="O11" value="1606.9" spread="670.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.5" spread="61.83"/>
                    <measurement group_id="O2" value="759.7" spread="138.59"/>
                    <measurement group_id="O3" value="2038.8" spread="1076.99"/>
                    <measurement group_id="O4" value="3321.5" spread="1275.83"/>
                    <measurement group_id="O5" value="3809.1" spread="466.85"/>
                    <measurement group_id="O6" value="4063.1" spread="782.33"/>
                    <measurement group_id="O7" value="4588.4" spread="700.04"/>
                    <measurement group_id="O11" value="3548.8" spread="1310.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="3135.2" spread="485.70"/>
                    <measurement group_id="O9" value="4739.8" spread="2902.53"/>
                    <measurement group_id="O10" value="6460.2" spread="1632.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580</title>
        <time_frame>Escalation and Expansion Q2D Cohorts: C1D21 pre-dose (C=22 days [Escalation Q2D] and 28 days [Expansion Q2D]); Escalation QW Cohorts: C1D22 pre-dose (C= 28 days)</time_frame>
        <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580</title>
          <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.3" spread="42.92"/>
                    <measurement group_id="O2" value="265.5" spread="74.25"/>
                    <measurement group_id="O3" value="1080.0" spread="797.75"/>
                    <measurement group_id="O4" value="1720.0" spread="708.87"/>
                    <measurement group_id="O5" value="1739.7" spread="746.88"/>
                    <measurement group_id="O6" value="2135.0" spread="494.00"/>
                    <measurement group_id="O7" value="2700.0" spread="1088.94"/>
                    <measurement group_id="O11" value="2085.0" spread="672.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="270.0" spread="108.00"/>
                    <measurement group_id="O9" value="898.7" spread="618.68"/>
                    <measurement group_id="O10" value="1216.7" spread="841.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580</title>
        <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
        <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580</title>
          <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.983" lower_limit="2.00" upper_limit="4.07"/>
                    <measurement group_id="O2" value="2.150" lower_limit="1.98" upper_limit="4.05"/>
                    <measurement group_id="O3" value="2.033" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="3.917" lower_limit="1.18" upper_limit="4.02"/>
                    <measurement group_id="O5" value="2.050" lower_limit="1.00" upper_limit="23.82"/>
                    <measurement group_id="O6" value="4.033" lower_limit="0.97" upper_limit="23.00"/>
                    <measurement group_id="O7" value="4.000" lower_limit="1.98" upper_limit="6.02"/>
                    <measurement group_id="O8" value="4.150" lower_limit="3.20" upper_limit="5.12"/>
                    <measurement group_id="O9" value="3.150" lower_limit="1.00" upper_limit="7.88"/>
                    <measurement group_id="O10" value="3.100" lower_limit="2.12" upper_limit="7.27"/>
                    <measurement group_id="O11" value="3.108" lower_limit="0.98" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.050" lower_limit="2.10" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.050" lower_limit="2.00" upper_limit="6.12"/>
                    <measurement group_id="O4" value="2.000" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="2.992" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="2.808" lower_limit="1.98" upper_limit="4.00"/>
                    <measurement group_id="O7" value="12.792" lower_limit="2.13" upper_limit="23.45"/>
                    <measurement group_id="O11" value="2.192" lower_limit="1.87" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="3.150" lower_limit="2.80" upper_limit="3.17"/>
                    <measurement group_id="O9" value="3.033" lower_limit="2.10" upper_limit="23.80"/>
                    <measurement group_id="O10" value="3.950" lower_limit="2.87" upper_limit="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580</title>
        <time_frame>Escalation (Esc.) and Expansion (Exp.) Q2D: C1D21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D22 at multiple time-points (up to168 h) post-dose (C=28 days)</time_frame>
        <population>PK-evaluable population. t1/2z of TAK-580 could not be determined in cancer participants who were on Q2D regimen with a 48-hour dose interval since the duration of plasma PK sample collection within the dose interval was shorter than the anticipated t1/2z of TAK-580. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580</title>
          <population>PK-evaluable population. t1/2z of TAK-580 could not be determined in cancer participants who were on Q2D regimen with a 48-hour dose interval since the duration of plasma PK sample collection within the dose interval was shorter than the anticipated t1/2z of TAK-580. PK-evaluable population where data at specified time points was available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Cycle 1 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Cycle 1 Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="50.22" lower_limit="46.4" upper_limit="59.3"/>
                    <measurement group_id="O9" value="59.06" lower_limit="31.1" upper_limit="119.2"/>
                    <measurement group_id="O10" value="69.65" lower_limit="61.6" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580</title>
        <time_frame>Q2D Cohorts: Cycle1 Days 1 and 21 up to 24 hours post-dose (Cycle1 length= 22 days); QW Cohorts: Cycle2 Days 1 and 22 up to 7 hours post-dose (Cycle 2 length= 28 days)</time_frame>
        <population>CLr of TAK-580 could not be determined since urine samples were collected for a limited duration during a site visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O9">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O10">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O11">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580</title>
          <population>CLr of TAK-580 could not be determined since urine samples were collected for a limited duration during a site visit.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580</title>
        <time_frame>Cycle 1 Days 1 and 21 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length= 22 days)</time_frame>
        <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
            <description>TAK-580 20 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
            <description>TAK-580 40 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
            <description>TAK-580 80 mg, tablet, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
            <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
            <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O7">
            <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O8">
            <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
            <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
          </group>
        </group_list>
        <measure>
          <title>Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580</title>
          <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4799.7" spread="2570.95"/>
                    <measurement group_id="O2" value="11019.7" spread="655.03"/>
                    <measurement group_id="O3" value="30562.8" spread="16909.20"/>
                    <measurement group_id="O4" value="36061.9" spread="8904.40"/>
                    <measurement group_id="O5" value="50946.5" spread="10597.12"/>
                    <measurement group_id="O6" value="78993.3" spread="23713.60"/>
                    <measurement group_id="O7" value="66799.2" spread="7656.58"/>
                    <measurement group_id="O8" value="53522.2" spread="17337.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10679.2" spread="2571.83"/>
                    <measurement group_id="O2" value="21007.9" spread="3501.86"/>
                    <measurement group_id="O3" value="43294.2" spread="10403.72"/>
                    <measurement group_id="O4" value="99626.7" spread="29090.62"/>
                    <measurement group_id="O5" value="125540.2" spread="46299.79"/>
                    <measurement group_id="O6" value="156439.3" spread="26263.33"/>
                    <measurement group_id="O7" value="165002.1" spread="19899.97"/>
                    <measurement group_id="O8" value="127026.4" spread="38244.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580</title>
        <time_frame>Cycle 1 Days 1 and 22 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)</time_frame>
        <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
            <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O2">
            <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
          <group group_id="O3">
            <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
            <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
          </group>
        </group_list>
        <measure>
          <title>QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580</title>
          <population>The PK-evaluable population included all participants who had sufficient dosing data and TAK-580 concentration-time data to permit calculation of any TAK-580 parameters. PK-evaluable population where data at specified time points was available.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184534.4" spread="50225.97"/>
                    <measurement group_id="O2" value="278247.9" spread="128772.92"/>
                    <measurement group_id="O3" value="431723.3" spread="106266.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199210.4" spread="57957.62"/>
                    <measurement group_id="O2" value="339244.8" spread="149201.72"/>
                    <measurement group_id="O3" value="477700.2" spread="86620.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points</title>
        <description>The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.</description>
        <time_frame>Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
        <population>Pharmacodynamic (PD)-evaluable: all participants who had sufficient dosing and PD data,collected within protocol-specified window of sampling time.Participants who were evaluable for this measure at given time point were included. Data for this measure was not planned to be collected and analyzed for Q2D Dose Expansion Phase:Pharmacokinetic Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (wild type [WT]), naive to any prior anticancer therapy except ipilimumab, anti-programmed cell death-1 (PD-1), and anti-PD ligand-1 (PDL-1) monoclonal antibodies.</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O7">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O8">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points</title>
          <description>The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.</description>
          <population>Pharmacodynamic (PD)-evaluable: all participants who had sufficient dosing and PD data,collected within protocol-specified window of sampling time.Participants who were evaluable for this measure at given time point were included. Data for this measure was not planned to be collected and analyzed for Q2D Dose Expansion Phase:Pharmacokinetic Cohort.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Quant H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.0" lower_limit="-100" upper_limit="460"/>
                    <measurement group_id="O2" value="-93.5" lower_limit="-97" upper_limit="1235"/>
                    <measurement group_id="O3" value="-82.0" lower_limit="-96" upper_limit="-43"/>
                    <measurement group_id="O5" value="-51.0" lower_limit="-97" upper_limit="-5"/>
                    <measurement group_id="O6" value="-15.0" lower_limit="-95" upper_limit="22"/>
                    <measurement group_id="O7" value="-8.0" lower_limit="-8" upper_limit="-8"/>
                    <measurement group_id="O8" value="-71.0" lower_limit="-71" upper_limit="-71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Semi H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.5" lower_limit="-100" upper_limit="-89"/>
                    <measurement group_id="O2" value="-80.5" lower_limit="-100" upper_limit="2207"/>
                    <measurement group_id="O3" value="-70.0" lower_limit="-100" upper_limit="603"/>
                    <measurement group_id="O5" value="-24.5" lower_limit="-78" upper_limit="29"/>
                    <measurement group_id="O6" value="-27.0" lower_limit="-100" upper_limit="0"/>
                    <measurement group_id="O7" value="-12.0" lower_limit="-12" upper_limit="-12"/>
                    <measurement group_id="O8" value="-23.0" lower_limit="-23" upper_limit="-23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points</title>
        <description>The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.</description>
        <time_frame>Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])</time_frame>
        <population>PD-evaluable: all participants who had sufficient dosing and PD data, collected within protocol-specified window of sampling time. Participants who were evaluable for this measure at given time point were included. Data for this measure was not planned to be collected and analyzed for Q2D Dose Expansion Phase: Pharmacokinetic Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O2">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O4">
            <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (wild type [WT]), naive to any prior anticancer therapy except ipilimumab, anti-programmed cell death-1 (PD-1), and anti-PD ligand-1 (PDL-1) monoclonal antibodies.</description>
          </group>
          <group group_id="O6">
            <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
          </group>
          <group group_id="O7">
            <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
            <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
          </group>
          <group group_id="O8">
            <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
            <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points</title>
          <description>The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.</description>
          <population>PD-evaluable: all participants who had sufficient dosing and PD data, collected within protocol-specified window of sampling time. Participants who were evaluable for this measure at given time point were included. Data for this measure was not planned to be collected and analyzed for Q2D Dose Expansion Phase: Pharmacokinetic Cohort.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cPARP Quant H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-100.0" lower_limit="-100" upper_limit="-93"/>
                    <measurement group_id="O3" value="317.5" lower_limit="-15" upper_limit="650"/>
                    <measurement group_id="O5" value="-100.0" lower_limit="-100" upper_limit="-100"/>
                    <measurement group_id="O6" value="-33.5" lower_limit="-100" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cPARP Semi H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-96.0" lower_limit="-100" upper_limit="-92"/>
                    <measurement group_id="O3" value="-33.0" lower_limit="-33" upper_limit="-33"/>
                    <measurement group_id="O5" value="-11.0" lower_limit="-11" upper_limit="-11"/>
                    <measurement group_id="O6" value="-48.0" lower_limit="-100" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIM-1 Quant H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.0" lower_limit="265" upper_limit="265"/>
                    <measurement group_id="O2" value="136.0" lower_limit="64" upper_limit="650"/>
                    <measurement group_id="O3" value="158.0" lower_limit="90" upper_limit="625"/>
                    <measurement group_id="O5" value="-52.5" lower_limit="-65" upper_limit="-40"/>
                    <measurement group_id="O6" value="-23.5" lower_limit="-53" upper_limit="66"/>
                    <measurement group_id="O7" value="35.5" lower_limit="-29" upper_limit="100"/>
                    <measurement group_id="O8" value="960.0" lower_limit="960" upper_limit="960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIM-1 Semi H-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="723.5" lower_limit="47" upper_limit="1400"/>
                    <measurement group_id="O2" value="64.5" lower_limit="-84" upper_limit="2533"/>
                    <measurement group_id="O3" value="64.0" lower_limit="30" upper_limit="287"/>
                    <measurement group_id="O5" value="-41.0" lower_limit="-75" upper_limit="-7"/>
                    <measurement group_id="O6" value="-17.0" lower_limit="-49" upper_limit="28"/>
                    <measurement group_id="O7" value="-3.5" lower_limit="-15" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs are AEs that started after the first dose of study drug and no more than 30 days after the last dose of study drug (approximately Cycle 38 Days 52 [Q2D] and 58 [QW] in Escalation Phase; Cycle 49 Day 58 in Expansion Phase)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)</title>
          <description>TAK-580 20 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cy cle 38).</description>
        </group>
        <group group_id="E2">
          <title>Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)</title>
          <description>TAK-580 40 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E3">
          <title>Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)</title>
          <description>TAK-580 80 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E4">
          <title>Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)</title>
          <description>TAK-580 135 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E5">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E6">
          <title>Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)</title>
          <description>TAK-580 280 mg, tablets, orally, Q2D, in each 22-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E7">
          <title>Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E8">
          <title>QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)</title>
          <description>TAK-580 400 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E9">
          <title>QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E10">
          <title>QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)</title>
          <description>TAK-580 800 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 38).</description>
        </group>
        <group group_id="E11">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="E12">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF mutation-positive cutaneous melanoma, which in response to previous treatment with RAF inhibitors and/or MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="E13">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
        <group group_id="E14">
          <title>Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with NRAS mutation-positive cutaneous melanoma, which in response to previous treatment with MEK inhibitors had relapsed following an objective response, failed to demonstrate an objective response and/or could not tolerate such a regimen due to unacceptable toxicity.</description>
        </group>
        <group group_id="E15">
          <title>Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative cutaneous melanoma (WT), naive to any prior anticancer therapy except ipilimumab, PD-1, and PDL-1 monoclonal antibodies.</description>
        </group>
        <group group_id="E16">
          <title>Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF/NRAS mutation-negative melanoma (WT), who had received at least 1 line of prior anticancer therapy.</description>
        </group>
        <group group_id="E17">
          <title>Q2D Dose Expansion Phase: Pharmacokinetic Cohort</title>
          <description>TAK-580 200 mg, tablets, orally, on Days 1 through 21 in a 28-days treatment Cycle 1, followed by TAK-580 200 mg, tablets, orally, Q2D in each 28-days treatment cycle from Cycle 2 until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with any advanced solid tumor (excluding lymphoma, but including melanoma) who had failed or were not candidates for standard therapies or for whom no approved therapy was available.</description>
        </group>
        <group group_id="E18">
          <title>Q2D Dose Expansion Phase: TAK-580 (BRAF+)</title>
          <description>TAK-580 200 mg, tablets, orally, Q2D, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49) in participants with BRAF-mutation positive cutaneous melanoma.</description>
        </group>
        <group group_id="E19">
          <title>QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive</title>
          <description>TAK-580 600 mg, tablets, orally, QW, in each 28-days treatment cycle until disease progression, unacceptable toxicity, or participant discontinuation for any other reason (up to Cycle 49), in participants with NRAS mutation-positive cutaneous melanoma, naive to prior therapy with RAF and MEK inhibitors.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="11" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="7" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="9" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="9" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E17" events="13" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Reticulocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="6" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eyelash discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="19" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eyelid disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Scleral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="42" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E12" events="23" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E13" events="11" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="15" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" events="6" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="8" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="13" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="12" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="9" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ear lobe infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctival abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stoma site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="13" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="7" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E17" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="8" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="6" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood folate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Metastases to chest wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Breast oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="8" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="10" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="11" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="18" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="9" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="8" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="8" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Butterfly rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

